These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33791422)

  • 1. Investigations from the Belly of the Beast: N-Terminally Labeled Incretin Peptides That Are Both Potent Receptor Agonists and Stable to Protease Digestion.
    Berger AA; Leppkes J; Koksch B
    ACS Cent Sci; 2021 Mar; 7(3):400-402. PubMed ID: 33791422
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.
    Targher G; Mantovani A; Byrne CD
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):179-191. PubMed ID: 36620987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.
    Salameh TS; Rhea EM; Talbot K; Banks WA
    Biochem Pharmacol; 2020 Oct; 180():114187. PubMed ID: 32755557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major contributions of comparative endocrinology to the development and exploitation of the incretin concept.
    Conlon JM; Patterson S; Flatt PR
    J Exp Zool A Comp Exp Biol; 2006 Sep; 305(9):781-6. PubMed ID: 16902971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug discovery approaches targeting the incretin pathway.
    Deng X; Tavallaie MS; Sun R; Wang J; Cai Q; Shen J; Lei S; Fu L; Jiang F
    Bioorg Chem; 2020 Jun; 99():103810. PubMed ID: 32325333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of incretin agonists on endothelial nitric oxide synthase expression and nitric oxide synthesis in human coronary artery endothelial cells exposed to TNFα and glycated albumin.
    Garczorz W; Francuz T; Siemianowicz K; Kosowska A; Kłych A; Aghdam MR; Jagoda K
    Pharmacol Rep; 2015 Feb; 67(1):69-77. PubMed ID: 25560578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent and metabolically stable agonists for protease-activated receptor-2: evaluation of activity in multiple assay systems in vitro and in vivo.
    Kawabata A; Kanke T; Yonezawa D; Ishiki T; Saka M; Kabeya M; Sekiguchi F; Kubo S; Kuroda R; Iwaki M; Katsura K; Plevin R
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1098-107. PubMed ID: 14976227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mirror cutting-assisted orthogonal digestion enabling large-scale and accurate protein complex characterization].
    Han R; Zhao L; An Y; Liang Z; Zhao Q; Zhang L; Zhang Y
    Se Pu; 2022 Mar; 40(3):224-233. PubMed ID: 35243832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.
    Verspohl EJ
    Pharmacol Ther; 2009 Oct; 124(1):113-38. PubMed ID: 19545590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin Hormones and Type 2 Diabetes-Mechanistic Insights and Therapeutic Approaches.
    Boer GA; Holst JJ
    Biology (Basel); 2020 Dec; 9(12):. PubMed ID: 33339298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
    Ordóñez-Vázquez AL; Beltrán-Gall SM; Pal SC; Méndez-Sánchez N
    Med Sci Monit; 2022 Sep; 28():e938365. PubMed ID: 36093924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of C-terminally substituted tachykinin-like peptide agonists by means of aequorin-based luminescent assays for human and insect neurokinin receptors.
    Torfs H; Detheux M; Oonk HB; Akerman KE; Poels J; Van Loy T; De Loof A; Vassart G; Parmentier M; Vanden Broeck J
    Biochem Pharmacol; 2002 May; 63(9):1675-82. PubMed ID: 12007570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 spike protein-, main protease- and papain-like-protease-targeting peptides from seed proteins following gastrointestinal digestion: An
    Wong FC; Ong JH; Chai TT
    Phytomed Plus; 2021 Feb; 1(1):100016. PubMed ID: 35403082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a stable isotope labeled (SIL) peptide and an extended SIL peptide as internal standards to track digestion variability of an unstable signature peptide during quantification of a cancer biomarker, human osteopontin, from plasma using capillary microflow LC-MS/MS.
    Faria M; Halquist MS; Yuan M; Mylott W; Jenkins RG; Karnes HT
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Sep; 1001():156-68. PubMed ID: 26279007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
    Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
    Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing the Overall Proteome Coverage by Combining Protein Digestion by Tryp-N and Trypsin.
    Hawksworth JI; Denolf L; Timmerman E; Gevaert K
    Methods Mol Biol; 2023; 2718():1-10. PubMed ID: 37665451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases.
    Li Y; Li L; Hölscher C
    Rev Neurosci; 2016 Oct; 27(7):689-711. PubMed ID: 27276528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes.
    Farngren J; Ahrén B
    Metabolism; 2019 Oct; 99():25-31. PubMed ID: 31279738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.